Edition:
United States

Resmed Inc (RMD)

RMD on New York Consolidated

79.00USD
20 Oct 2017
Change (% chg)

$0.21 (+0.27%)
Prev Close
$78.79
Open
$79.18
Day's High
$79.44
Day's Low
$78.61
Volume
462,872
Avg. Vol
1,014,008
52-wk High
$81.87
52-wk Low
$56.59

Chart for

About

ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD),... (more)

Overall

Beta: 0.77
Market Cap(Mil.): $11,241.74
Shares Outstanding(Mil.): 142.30
Dividend: 0.35
Yield (%): 1.77

Financials

  Industry Sector
P/E (TTM): -- 163.65 16.52
EPS (TTM): -- -- --
ROI: -- 9.60 11.32
ROE: -- 14.98 15.18

BRIEF-RESMED WINS GERMAN PATENT INFRINGEMENT CASE BROUGHT BY FISHER & PAYKEL

* RESMED WINS GERMAN PATENT INFRINGEMENT CASE BROUGHT BY FISHER & PAYKEL

Oct 12 2017

BRIEF-Resmed ‍says German court concludes two of co's European patents have been infringed​

* ‍German court concludes that Fisher & Paykel Simplus, Eson and Eson 2 masks infringe two ResMed European patents​ Source text for Eikon: Further company coverage:

Oct 08 2017

UPDATE 1-German court suspends Resmed's complaint against NZ's Fisher & Paykel

WELLINGTON, Sept 29 A German court has suspended health appliance firm ResMed Inc's intellectual property proceedings against New Zealand's Fisher & Paykel Healthcare Corp, according to a statement from Fisher & Paykel.

Sep 28 2017

German court suspends Resmed's complaint against NZ's Fisher & Paykel

WELLINGTON, Sept 29 A German court suspended health appliance firm ResMed Inc's intellectual property proceedings against New Zealand's Fisher & Paykel Healthcare , the latter firm said in a statement to the stock exchange on Friday.

Sep 28 2017

BRIEF-Fisher & Paykel Healthcare says German court suspends patent proceedings against co

Sept 29 Fisher & Paykel Healthcare Corporation Ltd

Sep 28 2017

BRIEF-Resmed inc says CEO Michael Farrell's FY 2017 total compensation was $8.1 mln vs $7.5 mln in FY 2016

* Resmed inc says CEO Michael Farrell's FY 2017 total compensation was $8.1 million versus $7.5 million in fy 2016 - SEC filing Source text: (http://bit.ly/2hvqt7h) Further company coverage:

Sep 25 2017

BRIEF-Resmed Q4 GAAP earnings per share $0.71

* Resmed Inc. announces results for the fourth quarter of fiscal year 2017

Aug 01 2017

ResMed withdraws U.S. trade complaint against Fisher & Paykel Healthcare

WELLINGTON Health appliance firm ResMed Inc has dropped a complaint against New Zealand's Fisher & Paykel Healthcare at the U.S. International Trade Commission (USITC), Fisher & Paykel said on Wednesday.

May 17 2017

BRIEF-Resmed plans to renew its patent infringement case against Fisher & Paykel

* Statement by ResMed on plans to renew its patent infringement case against Fisher & Paykel

May 17 2017

ResMed withdraws U.S. trade complaint against Fisher & Paykel Healthcare

WELLINGTON Health appliance firm ResMed Inc has dropped a complaint against New Zealand's Fisher & Paykel Healthcare at the U.S. International Trade Commission (USITC), Fisher & Paykel said on Wednesday.

May 16 2017

Earnings vs. Estimates